Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Cardiovascular >> Angiogenesis >> Growth Factors >> TGF
Overview
Product name
Anti-TGF beta 1 antibody
See all TGF beta 1 products (17) ...
Description
Chicken polyclonal to TGF beta 1
Specificity
This product will recognise recombinant human TGF beta 1 and pTGF Beta 1.2 by various immunochemical techniques including neutralization, immunoblotting and ELISA. By immunoblotting and ELISA, the antibody shows less than 2 % crossreactivity with TGF Beta 2 and TGF Beta 3 and less than 15 % cross-reactivity with recombinant amphibian TGF Beta 5.
Tested applications
Inhibition Assay, ELISA, WBmore details
Cross reactivity
Reacts with
Human
Immunogen
Recombinant full length protein (mature protein)(Human), expressed in CHO cells.
Properties
Form
Liquid
Storage instructions
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage buffer
Preservative: None
Constituents: PBS
Concentration
Concentration information loading...
Purity
Immunogen affinity purified
Clonality
Polyclonal
Isotype
IgG
Research areas
Cancer >> Cancer Metabolism >> Response to hypoxia
Cancer >> Invasion/microenvironment >> Angiogenesis >> Angiogenic growth factors
Cancer >> Growth factors >> TGF
Stem Cells >> Signaling Pathways >> TGF beta >> Secreted
Signal Transduction >> Growth Factors/Hormones >> TGF
Cardiovascular >> Angiogenesis >> Growth Factors >> TGF
Applications
Show applications key
Our Abpromise guarantee covers the use of ab10518 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Inhibition Assay
ELISA
WB
Application notes
ELISA: For ELISAs, a working concentration of 0.5 to 1.0 µg/ml antibody is recommended. The detection limit for recombinant human TGF beta 1 is approximately 0.15 ng/well.
WB: For immunoblotting, a working concentration of 0.1 to 0.2 µg/ml antibody is recommended. The detection limit for recombinant human TGF beta 1 is approximately 1 ng/lane and 5 ng/lane under non-reducing and reducing conditions, respectively. Predicted molecular weight: 47 kDa for the unprocessed precursor; 25 kDa for the mature protein.
Inhib: Anti-Human TGF beta 1 neutralises the bioactivity of recombinant human TGF beta 1 by inhibiting cell proliferation using the IL4 dependent murine HT-2 cell line.
In this bioassay, recombinant human TGF beta 1 (0.25 ng/ml) is preincubated with various cencentrations of the antibody (0.1 to 1000 ng/ml) for 1 hour at room temperature in a 96-well microtiter plate. Following this pre-incubation, HT-2 cells are added to each well. The total volume of 100 µl, containing antibody at various concentrations, recombinant mouse IL-4 at 7.5 ng/ml, recombinant human TGF-Beta-1 at 0.25 ng/ml, and HT-2 cells at 1 x 105 cells/ml, is incubated for 48 hours at 37 °C in a 5 % CO2 humidified incubator. 3H-thymidine is added during the final four hours. Cells are harvested onto glass filters and the 3H-thymidine incorporated into DNA is measured.
The Neutralization Dose50 (ND50) for anti-human TGF beta 1 is approximately 5 to 10 ng/ml in the presence of 0.25 ng/ml of recombinant human TGF beta 1, using the murine HT-2 cell line. The ND50 of this antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of recombinant human TGF beta 1 that is present at a concentration just high enough to elicit a maximum response. The exact concentration of antibody required to neutralize recombinant human TGF beta 1 activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Target
Function
Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
Tissue specificity
Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage.
Involvement in disease
Defects in TGFB1 are the cause of Camurati-Engelmann disease (CE) [MIM:131300]; also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.
Sequence similarities
Belongs to the TGF-beta family.
Post-translational
modifications
Glycosylated.
The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
Cellular localization
Secreted > extracellular space > extracellular matrix.
Target information above from: UniProt accessionP01137
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- Camurati Engelmann disease antibody
- CED antibody
- Diaphyseal dysplasia 1 progressive antibody
see all
Database links
- Entrez Gene: 7040 Human
- Omim: 190180 Human
- SwissProt: P01137 Human
- Unigene: 645227 Human
References for Anti-TGF beta 1 antibody (ab10518)
ab10518 has not yet been referenced specifically in any publications.
Publishing research using ab10518? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"